UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/565,238	01/19/2006	Pnina Fishman	FISHMAN19B	9164
	7590 05/16/200 D NEIMARK, P.L.L.C	EXAMINER		
624 NINTH STREET, NW SUITE 300 WASHINGTON, DC 20001-5303			SINGH, SATYENDRA K	
			ART UNIT	PAPER NUMBER
			1657	
			MAIL DATE	DELIVERY MODE
			05/16/2008	PAPER

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

	Application No.	Applicant(s)	
	10/565,238	FISHMAN ET AL.	
Office Action Summary	Examiner	Art Unit	
	SATYENDRA K. SINGH	1657	
The MAILING DATE of this communication ap Period for Reply	pears on the cover sheet with the c	correspondence address	
A SHORTENED STATUTORY PERIOD FOR REPL WHICHEVER IS LONGER, FROM THE MAILING D - Extensions of time may be available under the provisions of 37 CFR 1. after SIX (6) MONTHS from the mailing date of this communication. - If NO period for reply is specified above, the maximum statutory period - Failure to reply within the set or extended period for reply will, by statut Any reply received by the Office later than three months after the mailin earned patent term adjustment. See 37 CFR 1.704(b).	PATE OF THIS COMMUNICATION 136(a). In no event, however, may a reply be tinwill apply and will expire SIX (6) MONTHS from e, cause the application to become ABANDONE	N. nely filed the mailing date of this communication. D (35 U.S.C. § 133).	
Status			
Responsive to communication(s) filed on 19 J This action is FINAL . 2b) ☑ This Since this application is in condition for allowated closed in accordance with the practice under the second	s action is non-final. ince except for formal matters, pro		
Disposition of Claims			
4) Claim(s) <u>1-20</u> is/are pending in the application 4a) Of the above claim(s) is/are withdra 5) Claim(s) is/are allowed. 6) Claim(s) is/are rejected. 7) Claim(s) is/are objected to. 8) Claim(s) <u>1-20</u> are subject to restriction and/or	wn from consideration.		
Application Papers			
9) The specification is objected to by the Examine 10) The drawing(s) filed on is/are: a) acc Applicant may not request that any objection to the Replacement drawing sheet(s) including the correct 11) The oath or declaration is objected to by the E	cepted or b) objected to by the land drawing(s) be held in abeyance. Section is required if the drawing(s) is objected to by the land drawing(s) is objected to be land drawing(s).	e 37 CFR 1.85(a). jected to. See 37 CFR 1.121(d).	
Priority under 35 U.S.C. § 119			
12) Acknowledgment is made of a claim for foreign a) All b) Some * c) None of: 1. Certified copies of the priority documen 2. Certified copies of the priority documen 3. Copies of the certified copies of the priority documen application from the International Burea * See the attached detailed Office action for a list	ts have been received. ts have been received in Application trity documents have been receive tu (PCT Rule 17.2(a)).	on No ed in this National Stage	
Attachment(s) 1) Notice of References Cited (PTO-892) 2) Notice of Draftsperson's Patent Drawing Review (PTO-948) 3) Information Disclosure Statement(s) (PTO/SB/08) Paper No(s)/Mail Date	4) Interview Summary Paper No(s)/Mail Da 5) Notice of Informal F 6) Other:	ate	

Application/Control Number: 10/565,238 Page 2

Art Unit: 1651

DETAILED ACTION

Election/Restrictions

1. Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claim(s) 1-7, drawn to a method for determining an inflammatory state, or the severity of an inflammatory state in a subject comprising determining the level of expression of A3 adenosine receptor (A3AR) in white blood cells (WBCs) from said subject.

Group II, claim(s) 8-14, drawn to a method for determining the effectiveness of an anti-inflammatory therapeutic treatment of a subject comprising administering an A3AR agonist to the subject and determining the expression level of A3AR in WBCs from said subject, as specifically recited in claim 8.

Group III, claim(s) 15-20, drawn to a method for selecting a subject suffering from a certain inflammatory disease, as specifically recited in instant claim 15.

NOTE: Claim 18 improperly depends on itself, accordingly it has been taken to be dependent from instant claim 15, and grouped with the invention of group III. Appropriate amendment/correction is requested.

- 2.
- (a) An international or national stage application shall relate to one invention only or to a group of inventions so linked as to form a single general inventive concept. Where a group of inventions is claimed in an application, the requirement of unity of invention shall be fulfilled only when there is a technical relationship among those invention involving one or more of the same or corresponding special technical features. The expression "special technical features" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art.
- (b) An international or a national stage application containing claims to different categories of invention will be considered to have unity of invention if the claims are drawn only to one of the following combinations of categories:
- (1) a product and a process specially adapted for the manufacture of said product; or

Application/Control Number: 10/565,238

Page 3

Art Unit: 1651

(2) a product and a process of use of said product; or

- (3) a product, a process specially adapted for the manufacture of the said product, and a use of the said product; or
- (4) a process and an apparatus or means specifically designed for carrying out said process; or
- (5) a product, a process specially adapted for the manufacture of the said product and an apparatus or means specifically designed for carrying out said process. (c) If an application contains claims to more or less than one of the combinations of categories of invention set forth in paragraph (b) of this section, unity of invention might not be present.

The groups of inventions as recited in groups (I-III) do not fall within any of the categories discussed above.

PCT Rule 13.2 does not provide for multiple compositions or **multiple methods** of use within a single application. Thus, the first appearing composition is combined with a corresponding first method of use and the additional composition and method claims each constitute a separate group.

In addition to the requirement that a group of inventions must belong to one of the specific categories provided by PCT Rule 13.2, the inventions in the category, such as a composition and a method of use of the composition, must have a special technical feature that unites them. See Patent Rules 1.475, where a special technical feature is a contribution OVER THE PRIOR ART.

Thus, the inventions listed as Groups (I-III) do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding special technical features as demonstrated above. Since the composition AS CLAIMED is known in the art, see **Szabo et al** (1998, IDS citation # AN, abstract, in particular) that clearly show the relationship between A3AR (one of the various known adenosine receptors that have been known in the art to modulate the production of pro- and anti-inflammatory cytokines; see introduction, in particular) and inflammatory conditions due to collagen-induced arthritis (also reveals an A3AR agonist that exerts anti-inflammatory effects in macrophages), no special technical feature unites these inventions in a category.

The expression "special technical feature" shall mean those technical features that define a contribution which each of the claimed inventions, considered as a whole, makes over the prior art (PCT Rule 13.2). Thus, a feature found in the prior art cannot be considered to be a special technical feature.

Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.143).

4. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim

Application/Control Number: 10/565,238 Page 4

Art Unit: 1651

remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

5. Any inquiry concerning this communication or earlier communications from the examiner should be directed to SATYENDRA K. SINGH whose telephone number is (571)272-8790. The examiner can normally be reached on 9-5MF.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jon P. Weber can be reached on 571-272-0925. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see http://pair-direct.uspto.gov. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

/Sandra Saucier/ Primary Examiner, Art Unit 1651

/Satyendra K. Singh/ Examiner, Art Unit 1657